A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

BP2201 - BrightPath Biotherap

http://www.ncbi.nlm.nih.gov/pubmed/41746943

Haruhiko Koseki; Haruna Ebisu; Hideki Hanaoka; Shinichiro Motohashi; Tadami Fujiwara; Takahiro Aoki; Tominaga Fukazawa; Tomoha Yanagidaira; Tomohisa Iinuma; Tomoya Kurokawa; Toyoyuki Hanazawa; Yoko Hattori; Yosuke Inaba

Feb 26, 2026